Moderate-to-Severe Asthma: Targeting Underlying Inflammatory Processes to Improve Patient Outcomes

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology

Sunday, November 7, 2021

6:00 PM – 6:30 PM – Dinner/Registration
6:30 PM – 7:30 PM – Symposium

Hilton New Orleans Riverside Hotel
2 Poydras Street
New Orleans, LA 70130
Grand Ballroom Salon B (1st Floor)

Program Features

  • Simulation animation challenge
  • Interactive, case-based learning
  • Complimentary personalized online poster portal


Diego J Maselli, MD
Associate Professor of Medicine
Division of Pulmonary Diseases & Critical Care
University of Texas Health Science Center at San Antonio
Director, Severe Asthma Program
University Health System
San Antonio, TX

Nicola A Hanania, MD
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Houston, TX

Target Audience

This activity is designed to meet the needs of allergists, immunologists, and other health care providers involved in the care of patients with moderate-to-severe asthma.

Learning Objectives

After completing the activity, learners should be better able to:

  • Utilize knowledge of the type 2 inflammatory pathway to select therapies that target the underlying chronic inflammation associated with severe asthma and other commonly comorbid conditions
  • Assess disease severity and identify patients who require step-up therapy to manage symptoms, minimize systemic steroid use and reduce emergency room visits
  • Design evidence-based treatment plans for pediatric and adult patients with moderate-to-severe asthma that include patient-specific factors, such as comorbidities, quality of life, and treatment responses


Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the virtual event at